Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives

Core Insights - Attovia Therapeutics has successfully closed a $105 million oversubscribed Series B financing, increasing total capital raised to $165 million since its inception in June 2023 [1][2] Financing Details - The Series B financing was led by Goldman Sachs Alternatives, with participation from both new and existing investors including Cormorant Asset Management, Nextech Ventures, Redmile Group, EcoR1 Capital, Marshall Wace, and Logos Capital [2] - Existing investors such as Frazier Life Sciences, venBio, and Illumina Ventures also participated in this financing round [2] - Colin Walsh, Ph.D., from Goldman Sachs Alternatives, has been appointed to Attovia's Board of Directors concurrent with the financing [2] Company Strategy and Pipeline - The proceeds from the financing will be utilized to advance lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts, expand the immunology and inflammation pipeline, and further develop the ATTOBODY™ platform [1][3] - ATTO-1310 is positioned as a potential first-in-class anti-IL31 ATTOBODY, currently in IND enabling studies, expected to enter clinical trials by the end of 2024 for treating atopic dermatitis and other pruritic diseases [3] - ATTO-002, a bispecific anti-IL31 x IL13 ATTOBODY, is anticipated to have a development candidate nominated in the second half of 2024, with plans to advance to IND in 2025 [3] - The company is also working on discovery stage programs to expand the ATTOBODY platform to novel, difficult-to-drug targets [3] Technology and Product Development - Attovia's ATTOBODY™ platform generates spatially optimized biparatopic biologics, which are designed to offer stronger efficacy and a broader range of druggable epitopes compared to traditional methods [5][6] - The biparatopic binding mode of ATTOBODIES provides picomolar affinity and strong potency, with the ability to functionalize biologically inactive epitopes [6] - The platform allows for modular engineering into multispecifics and offers tunable half-lives from hours to weeks, significantly accelerating development and expanding target biology coverage [6] Market Position and Future Outlook - Attovia is positioned to become a leader in developing best-in-class novel biologics for immune-mediated diseases, leveraging its differentiated pipeline and proprietary platform [4][3] - The strong investor interest reflects the rapid progress made since the company's inception and the potential for future business development opportunities [3][4]